Total Payments
$58,066
2024 Payments
$10,134
Companies
14
Transactions
83
Medicare Patients
1,131
Medicare Billing
$169,305
Payment Breakdown by Category
Consulting$38,203 (65.8%)
Other$8,350 (14.4%)
Travel$8,186 (14.1%)
Food & Beverage$1,811 (3.1%)
Research$1,416 (2.4%)
Education$99.00 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $38,203 | 17 | 65.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,350 | 3 | 14.4% |
| Travel and Lodging | $8,186 | 24 | 14.1% |
| Food and Beverage | $1,811 | 29 | 3.1% |
| Unspecified | $1,416 | 9 | 2.4% |
| Education | $99.00 | 1 | 0.2% |
Payments by Type
General
$56,649
74 transactions
Research
$1,416
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $25,612 | 21 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $16,539 | 25 | $0 (2023) |
| BeiGene, Ltd. | $4,927 | 2 | $0 (2021) |
| ABBVIE INC. | $4,837 | 8 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $1,635 | 1 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $1,477 | 8 | $0 (2018) |
| Genmab A/S | $1,416 | 9 | $0 (2023) |
| Janssen Research & Development, LLC | $1,163 | 2 | $0 (2018) |
| Janssen Biotech, Inc. | $137.72 | 1 | $0 (2023) |
| BeiGene USA, Inc. | $128.56 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,134 | 11 | AstraZeneca Pharmaceuticals LP ($5,328) |
| 2023 | $9,300 | 22 | AstraZeneca Pharmaceuticals LP ($5,474) |
| 2022 | $7,785 | 9 | AstraZeneca Pharmaceuticals LP ($7,734) |
| 2021 | $8,396 | 4 | BeiGene, Ltd. ($4,927) |
| 2020 | $3,707 | 3 | AstraZeneca Pharmaceuticals LP ($3,608) |
| 2019 | $4,886 | 10 | Pharmacyclics LLC, An AbbVie Company ($4,861) |
| 2018 | $13,799 | 23 | Pharmacyclics LLC, An AbbVie Company ($11,158) |
| 2017 | $59.74 | 1 | Foundation Medicine, Inc. ($59.74) |
All Payment Transactions
83 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $937.50 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,870.00 | General |
| 12/08/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $93.74 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $78.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: Oncology | ||||||
| 10/19/2024 | AstraZeneca Pharmaceuticals LP | LUMOXITI (Biological) | Consulting Fee | Cash or cash equivalent | $2,397.50 | General |
| Category: Oncology | ||||||
| 09/10/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $110.88 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $590.14 | General |
| Category: ONCOLOGY | ||||||
| 05/31/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $365.12 | General |
| Category: ONCOLOGY | ||||||
| 05/31/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $131.29 | General |
| Category: ONCOLOGY | ||||||
| 12/14/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| Category: Oncology | ||||||
| 12/09/2023 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $137.72 | General |
| Category: Oncology | ||||||
| 12/08/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 12/08/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $48.58 | General |
| 12/08/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $25.62 | General |
| 10/08/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $108.66 | General |
| Category: ONCOLOGY | ||||||
| 09/22/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,397.50 | General |
| Category: Oncology | ||||||
| 09/20/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $312.50 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $20.52 | General |
| Category: Oncology | ||||||
| 07/18/2023 | Janssen Scientific Affairs, LLC | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $1,635.00 | General |
| Category: Oncology | ||||||
| 05/19/2023 | Genmab A/S | Epkinly (Drug) | — | Cash or cash equivalent | $215.12 | Research |
| Study: A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. • Category: Oncology | ||||||
| 05/19/2023 | Genmab A/S | Epkinly (Drug) | — | Cash or cash equivalent | $164.00 | Research |
| Study: A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. • Category: Oncology | ||||||
| 05/19/2023 | Genmab A/S | Epkinly (Drug) | — | Cash or cash equivalent | $125.00 | Research |
| Study: A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. • Category: Oncology | ||||||
| 05/19/2023 | Genmab A/S | Epkinly (Drug) | — | Cash or cash equivalent | $87.00 | Research |
| Study: A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. • Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia. | Genmab A/S | $1,416 | 9 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 335 | 520 | $139,580 | $40,967 |
| 2022 | 5 | 252 | 532 | $122,315 | $39,924 |
| 2021 | 5 | 280 | 548 | $129,730 | $43,788 |
| 2020 | 7 | 264 | 593 | $142,395 | $44,626 |
Total Patients
1,131
Total Services
2,193
Medicare Billing
$169,305
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 42 | 156 | $49,920 | $14,161 | 28.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 122 | 148 | $32,560 | $10,937 | 33.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 124 | 167 | $36,170 | $10,360 | 28.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 27 | 28 | $14,420 | $3,663 | 25.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 20 | 21 | $6,510 | $1,845 | 28.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 168 | 354 | $70,885 | $23,828 | 33.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 39 | 132 | $34,320 | $10,624 | 31.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 13 | $6,500 | $2,046 | 31.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 22 | 22 | $5,830 | $1,816 | 31.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 11 | 11 | $4,780 | $1,610 | 33.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 161 | 337 | $65,715 | $23,984 | 36.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 45 | 137 | $35,620 | $10,731 | 30.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 27 | 27 | $13,500 | $4,184 | 31.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 31 | 31 | $8,215 | $2,585 | 31.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 16 | 16 | $6,680 | $2,305 | 34.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 114 | 281 | $54,795 | $16,233 | 29.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 52 | 199 | $50,745 | $16,196 | 31.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 31 | 35 | $17,150 | $5,544 | 32.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 29 | 35 | $9,100 | $3,006 | 33.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 13 | 13 | $5,330 | $1,775 | 33.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 11 | 13 | $3,575 | $1,167 | 32.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 14 | 17 | $1,700 | $704.41 | 41.4% |
About Dr. Seema Bhat, MD
Dr. Seema Bhat, MD is a Hematology & Oncology healthcare provider based in Columbus, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2008. The National Provider Identifier (NPI) number assigned to this provider is 1558524926.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Seema Bhat, MD has received a total of $58,066 in payments from pharmaceutical and medical device companies, with $10,134 received in 2024. These payments were reported across 83 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($38,203).
As a Medicare-enrolled provider, Bhat has provided services to 1,131 Medicare beneficiaries, totaling 2,193 services with total Medicare billing of $169,305. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology
- Location Columbus, OH
- Active Since 07/07/2008
- Last Updated 07/29/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1558524926
Products in Payments
- CALQUENCE (Drug) $19,069
- Imbruvica (Drug) $16,118
- VENCLEXTA (Drug) $4,837
- BRUKINSA (Drug) $3,106
- LUMOXITI (Biological) $2,398
- IMBRUVICA (Drug) $2,193
- Epkinly (Drug) $1,437
- DARZALEX (Biological) $1,155
- FOUNDATIONONE (Device) $59.74
- VENCLEXTA (Biological) $24.95
- DARZALEX (Drug) $7.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Columbus
David Carbone, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $655,286
Hematology & Oncology $655,286
Spero Cataland, M.d, M.D
Hematology & Oncology — Payments: $249,112
Hematology & Oncology $249,112
Sam Penza, M.d, M.D
Hematology & Oncology — Payments: $247,603
Hematology & Oncology $247,603
Nadeem Ikhlaque, Md, MD
Hematology & Oncology — Payments: $124,067
Hematology & Oncology $124,067
Hannah Choe, M.d, M.D
Hematology & Oncology — Payments: $75,011
Hematology & Oncology $75,011
Erin Bertino, Md, MD
Hematology & Oncology — Payments: $71,650
Hematology & Oncology $71,650